Drug intelligence / Profile preview

albuterol sulfate + mometasone furoate

Development stage: Preclinical
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration: Inhalation

Overview

This combination medication pairs albuterol sulfate, a short-acting beta-2 adrenergic receptor agonist that provides quick bronchodilation, with mometasone furoate, an inhaled corticosteroid that reduces airway inflammation. Albuterol works by relaxing bronchial smooth muscle to open airways rapidly, typically within 5-15 minutes, with effects lasting 3-6 hours. Mometasone works by preventing inflammation in the lungs that can trigger asthma attacks. This combination would theoretically provide both immediate symptom relief and long-term control of asthma.

Targets

GR (Glucocorticoid receptor)ADRB2 (β2)

Beyond the preview

Go deeper on albuterol sulfate + mometasone furoate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on albuterol sulfate + mometasone furoate.

Explore the full profile